Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rapid Dose Therapeutics Corp ( (TSE:DOSE) ) has issued an announcement.
Rapid Dose Therapeutics has provided an update on cannabinoid-focused research and clinical work involving its QuickStrip oral thin film platform. Independent researchers at the University of Regina and the University of Saskatchewan, supported by National Football League grant funding, are studying naturally produced cannabinoids in pain management and neuroprotection for concussion and contact sports.
In a parallel clinical arm launched in Q2 2024, investigators are assessing the bioavailability of cannabidiol delivered via QuickStrip versus traditional oral formats, with more than 60% of participant data already collected and further enrollment continuing into Q2 2026. The company says the ongoing bioavailability and stability studies support the potential of QuickStrip to offer rapid, discreet and efficient cannabinoid delivery, reinforcing its broader applicability across pharmaceutical and wellness applications and potentially enhancing its competitive position in drug delivery solutions.
The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.15 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.
Spark’s Take on TSE:DOSE Stock
According to Spark, TipRanks’ AI Analyst, TSE:DOSE is a Neutral.
The score is primarily weighed down by weak financial performance (persistent large losses, negative equity, and ongoing cash burn). Technicals add caution with the stock trading below major moving averages and negative MACD, while valuation is difficult to justify with a negative P/E and no dividend yield data.
To see Spark’s full report on TSE:DOSE stock, click here.
More about Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp. is a Canadian biotechnology company specializing in innovative drug delivery technologies. Its flagship QuickStrip oral thin film platform delivers active ingredients such as nutraceuticals, pharmaceuticals and vaccines rapidly into the bloodstream, targeting both pharmaceutical and wellness markets that value fast, discreet administration.
Average Trading Volume: 48,987
Technical Sentiment Signal: Sell
Current Market Cap: C$21.1M
For detailed information about DOSE stock, go to TipRanks’ Stock Analysis page.